A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive Breast Cancer|ER-positive Breast Cancer
Interventions: DRUG: SHR6390|DRUG: Anastrozole|DRUG: Pyrotinib|DRUG: Trastuzumab
Sponsor: Ruijin Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.